Page 143 - 南京医科大学学报自然科学版
P. 143
第41卷第9期 顾茹辛,仲 敏,张 丽. 帕金森病视幻觉发生机制研究进展[J].
2021年9月 南京医科大学学报(自然科学版),2021,41(09):1406-1410 ·1409 ·
GABA能降低驱动内源信息入侵,可能是VH产生的 sual hallucinations[J]. Brain Commun,2019,1(1):
一种机制。DLB的一项神经病理学研究显示,DLB患 fcz007
者的视皮层 GABA 能活性降低 [44] 。Firbank 等 [45] 在 [7] LEE W W,YOON E J,JY L,et al. Visual hallucination
PD⁃VH患者中通过fMRI发现相似结果,PD⁃VH患者 and pattern of brain degeneration in parkinson’s disease
[J]. Neurodegener Dis,2017,17(2/3):63-72
枕叶GABA/肌酸比值明显下降,可能因视觉刺激减
[8] BALESTRINO R,SCHAPIRA A. Parkinson disease[J].
少而代偿性下降。同时提出,由于5⁃HT受体可以调
Eur J Neurol,2020,27(1):27-42
节 GABA 的释放,恩丹西酮、匹莫范色林等拮抗 5⁃ [9] BRAAK H,DEL TREDICI K. Neuropathological staging
HT 受体药物可能部分作用于 GABA 能系统来治疗 of brain pathology in sporadic Parkinson’s disease:sepa⁃
幻觉。GABA 减少如何引起 VH 的具体机制还需要 rating the wheat from the chaff[J]. J Parkinsons Dis,
多模态研究来确定。 2017,7(s1):S73-S87
[10] MARINUS J,ZHU K,MARRAS C,et al. Risk factors for
4 总结与展望
non⁃motor symptoms in Parkinson’s disease[J]. Lancet
Neurol,2018,17(6):559-568
视幻觉是常见的 PD 精神障碍,增加 PD 患者的
[11] POWELL A,IRELAND C,LEWIS S. Visual hallucina⁃
并发症及病死率,严重影响 PD 患者及其家属的生
tions and the role of medications in Parkinson’s disease:
活质量。由于视幻觉症状评定依赖于患者主观描
triggers,pathophysiology,and management[J]. J Neuro⁃
述,缺乏标准精神症状检测量表,所以PD患者幻觉 psychiatry Clin Neurosci,2020,32(4):334-343
症状评定存在偏倚。因此探索其发生机制具有重 [12] JANZEN J,VAN ’D,LEMSTRA A W,et al. The pedun⁃
要临床意义,为早期诊断、有效干预提供更多思 culopontine nucleus is related to visual hallucinations in
路。国外学者评估 PD⁃VH 选用的量表尚无统一标 Parkinson’s disease:preliminary results of a voxel⁃based
准,包括神经精神量表、阳性症状评估时间表、简明 morphometry study[J]. J Neurol,2012,259(1):147-154
精神病评定量表等,特异性和敏感性有待考证。国 [13] GOLDMAN J G,STEBBINS G T,DINH V,et al. Visuoper⁃
ceptive region atrophy independent of cognitive status in
内关于VH研究较少,尚无相关检测工具,急需研究
patients with Parkinson’s disease with hallucinations[J].
者积极研制 PD⁃VH 特异评价量表。目前用于研究
Brain,2014,137(3):849-859
PD精神症状的动物模型极为缺乏,行为学判定难度
[14] LENKA A,INGALHALIKAR M,SHAH A,et al. Hippo⁃
较大,未来可采用多变量研究方式建立涵盖PD运动 campal subfield atrophy in patients with Parkinson’s dis⁃
症状和非运动症状的动物模型,为进一步探讨PD精 ease and psychosis[J]. J Neural Transm(Vienna),2018,
神症状的病理生理机制提供基础,指导临床工作。 125(9):1361-1372
[15] SHIN S,LEE J E,JY H,et al. Neuroanatomical substrates
[参考文献]
of visual hallucinations in patients with non ⁃ demented
[1] 中华医学会神经病学分会帕金森病及运动障碍学组. Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry,
中国医师协会神经内科医师分会帕金森病及运动障碍 2012,83(12):1155-1161
学组[J]. 中华神经科杂志,2020,53(12):973-986 [16] ZARKALI A,MCCOLGAN P,LEYLAND L A,et al. Fiber
[2] ARMSTRONG M J,OKUN M S. Diagnosis and treatment ⁃specific white matter reductions in Parkinson hallucina⁃
of parkinson disease:a review[J]. JAMA,2020,323(6): tions and visual dysfunction[J]. Neurology,2020,94
548-560 (14):e1525-e1538
[3] SCHAPIRA A,CHAUDHURI K R,JENNER P. Non⁃mo⁃ [17] HALL J M,O’CALLAGHAN C,MULLER A J,et al.
tor features of Parkinson disease[J]. Nat Rev Neurosci, Changes in structural network topology correlate with se⁃
2017,18(8):509 verity of hallucinatory behavior in Parkinson’s disease
[4] CLEGG B J,DUNCAN G W,KHOO T K,et al. Categoris⁃ [J]. Netw Neurosci,2019,3(2):521-538
ing visual hallucinations in early Parkinson’s disease[J]. [18] KURITA A,KOSHIKAWA H,AKIBA T,et al. Visual hal⁃
J Parkinson’s Dis,2018,8(3):447-453 lucinations and impaired conscious visual perception in
[5] LENKA A,PAGONABARRAGA J,PAL P K,et al. Minor Parkinson disease[J]. J Geriatr Psychiatry Neurol,2020,
hallucinations in Parkinson disease[J]. Neurology,2019, 33(6):377-385
93(6):259-266 [19] VISSER F,APOSTOLOV V I,VLAAR A,et al. Visual
[6] ZARKALI A,ADAMS R A,PSARRAS S,et al. Increased hallucinations in Parkinson’s disease are associated with
weighting on prior knowledge in Lewy body⁃associated vi⁃ thinning of the inner retina[J]. Sci Rep,2020,10(1):